Pfizer advances an abuse-deterrent pain med; Chinese-born scientists return home for biotech;

@FierceBiotech: Eisai wins an early FDA nod for its self-described cancer blockbuster. Report | Follow @FierceBiotech

@JohnCFierce: Biotech boom drives blockbuster VC investments in Boston, San Francisco. Story | Follow @JohnCFierce

@DamianFierce: Eisai exec told WSJ yesterday that lenvatinib approval was "imminent." Well. FDA announcement | Follow @DamianFierce

> The FDA has accepted Pfizer's ($PFE) application for ALO-02, an abuse-deterrent painkiller that combines oxycodone and naltrexone. The company didn't disclose when it expects to get a final ruling from the agency. More

> A generation of Chinese scientists who once left the country for jobs in western pharma are returning home, lured by the nascent biotech ecosystem there, Reuters reports. Story

Medical Device News

@FierceMedDev: J&J joins forces with JDRF for type 1 diabetes Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: NIH discusses 'precision medicine' genomics initiative and how to build a million-person research cohort. Item | Follow @VarunSaxena2

@EmilyWFierce: Better training for pediatricians could help increase use of IUDs in teenage girls. Story from The Atlantic | Follow @EmilyWFierce

> USAID backs wearable tech initiative for Ebola from Scripps. Article

> Disposable insulin device maker Valeritas files to raise up to $90M in an IPO. Report

Pharma News

@FiercePharma: UPDATED: Valeant, Shire prep Salix bids. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere. Report | Follow @CarlyHFierce

> Activists ready to fight for Ariad CEO's ouster: CNBC. More

> Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU. Article

> England's price watchdog writes off Celgene's Imnovid in final guidance. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.